source
- NeuShen Therapeutics raises over $80 million to advance three brain-health drug candidatesNeuShen Therapeutics, a biotech with operations in Shanghai and Boston, announced it has closed a Series B financing round of more than $80 million. The capital will be used to move three clinical…
- Bristol Myers Squibb pauses autoimmune CAR‑T trials after life‑threatening side effectsBristol Myers Squibb announced in early June that it is pausing its CAR‑T therapy trials targeting autoimmune diseases after the trials reported life‑threatening side effects. The company informed…